Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACSTNASDAQ:ASNDNYSE:NBYNASDAQ:NEPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACSTAcasti Pharma$3.11$3.22$1.98▼$3.60$29.23M1.5222,722 shs12,261 shsASNDAscendis Pharma A/S$157.27-2.9%$157.21$111.09▼$183.00$9.59B0.41487,215 shs370,095 shsNBYNovaBay Pharmaceuticals$0.57-0.7%$0.57$0.36▼$6.30$3.29M0.42147,005 shs19,155 shsNEPTNeptune Wellness Solutions$0.39$0.19▼$28.00$906K2.19462,687 shs2.25 million shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACSTAcasti Pharma0.00%0.00%0.00%-7.72%+14.34%ASNDAscendis Pharma A/S-2.92%-2.66%-4.19%+3.05%+20.60%NBYNovaBay Pharmaceuticals-0.68%-4.12%-2.45%-9.46%-87.73%NEPTNeptune Wellness Solutions0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACSTAcasti PharmaN/AN/AN/AN/AN/AN/AN/AN/AASNDAscendis Pharma A/S3.5167 of 5 stars4.53.00.00.03.51.70.6NBYNovaBay Pharmaceuticals1.8807 of 5 stars3.50.00.00.00.61.71.3NEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACSTAcasti Pharma 3.00Buy$10.00221.54% UpsideASNDAscendis Pharma A/S 3.00Buy$216.0737.39% UpsideNBYNovaBay Pharmaceuticals 3.00Buy$0.8550.23% UpsideNEPTNeptune Wellness Solutions 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NBY, ACST, NEPT, and ASND Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025ASNDAscendis Pharma A/SCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$200.00 ➝ $200.005/5/2025ASNDAscendis Pharma A/SMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$180.00 ➝ $250.005/2/2025ASNDAscendis Pharma A/SRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$205.00 ➝ $210.005/2/2025ASNDAscendis Pharma A/SJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$200.00 ➝ $245.005/2/2025ASNDAscendis Pharma A/SWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$181.00 ➝ $212.005/2/2025ASNDAscendis Pharma A/SEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$260.00 ➝ $280.004/16/2025ASNDAscendis Pharma A/SRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$205.003/18/2025ASNDAscendis Pharma A/SJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$168.00 ➝ $200.00(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACSTAcasti PharmaN/AN/AN/AN/A$6.57 per shareN/AASNDAscendis Pharma A/S$368.70M26.01N/AN/A($1.88) per share-83.65NBYNovaBay Pharmaceuticals$9.78M0.34N/AN/A$4.25 per share0.13NEPTNeptune Wellness Solutions$52.62M0.00N/AN/A($91.90) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACSTAcasti Pharma-$12.85M-$1.44N/AN/AN/AN/A-13.61%-11.56%N/AASNDAscendis Pharma A/S-$409.12M-$6.28N/A655.29N/A-104.54%N/A-39.23%N/ANBYNovaBay Pharmaceuticals-$9.64M-$53.72N/AN/AN/A-102.72%-7,293.78%-158.41%N/ANEPTNeptune Wellness Solutions-$60.46M-$106.72N/AN/AN/A-128.13%N/A-141.94%N/ALatest NBY, ACST, NEPT, and ASND EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025Q1 2025ASNDAscendis Pharma A/S-$1.56-$1.66-$0.10-$1.66$98.56 million$123.97 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACSTAcasti PharmaN/AN/AN/AN/AN/AASNDAscendis Pharma A/SN/AN/AN/AN/AN/ANBYNovaBay PharmaceuticalsN/AN/AN/AN/AN/ANEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACSTAcasti PharmaN/A7.867.86ASNDAscendis Pharma A/SN/A1.170.84NBYNovaBay PharmaceuticalsN/A1.150.91NEPTNeptune Wellness SolutionsN/A0.230.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACSTAcasti Pharma6.08%ASNDAscendis Pharma A/SN/ANBYNovaBay Pharmaceuticals23.25%NEPTNeptune Wellness Solutions14.44%Insider OwnershipCompanyInsider OwnershipACSTAcasti Pharma13.51%ASNDAscendis Pharma A/S40.00%NBYNovaBay Pharmaceuticals0.10%NEPTNeptune Wellness Solutions5.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACSTAcasti Pharma329.40 million8.77 millionNot OptionableASNDAscendis Pharma A/S64060.97 million36.41 millionOptionableNBYNovaBay Pharmaceuticals305.82 million4.88 millionNot OptionableNEPTNeptune Wellness Solutions584.53 million4.30 millionNot OptionableNBY, ACST, NEPT, and ASND HeadlinesRecent News About These Companiest20 world cup 2020 teamsDecember 28, 2024 | bweducation.businessworld.inNeptune Wellness Solutions Inc. (NEPTF)November 27, 2024 | finance.yahoo.comThree Breakthrough Strategies To Revolutionize Pain Relief And WellnessNovember 7, 2024 | forbes.comThe Aesthetic Experience introduces AE WellnessNovember 7, 2024 | koin.comNeptune homeless camp down to 13 people as deadline to shut it down is nearly hereOctober 18, 2024 | app.comThe Next Era of Lenovo Neptune Water Cooling Arrives to Efficiently Power NVIDIA Blackwell Platform and AI at Every ScaleOctober 15, 2024 | valdostadailytimes.comOpen Letter to Dominican President Luis Abinader: Stop Deportations Now!October 12, 2024 | counterpunch.org2024 Wellness Olympia Results & Prize Money — Isabelle Nunes Wins 1st TitleOctober 12, 2024 | fitnessvolt.comKroger Wellness Festival canceled, products will go to people impacted by HeleneSeptember 28, 2024 | local12.comRestore Hyper Wellness and MECOTEC Announce Strategic Partnership in Cryotherapy SolutionsSeptember 24, 2024 | tmcnet.comCapitol Wellness Solutions opens new medical marijuana dispensary in Baton RougeSeptember 21, 2024 | yahoo.comCapitol Wellness Solutions opened a new medical marijuana dispensary, for the first time in LouisianaSeptember 21, 2024 | msn.comGiant space balloon ‘Spaceship Neptune-Excelsior’ completes 2nd test flight in TitusvilleSeptember 19, 2024 | clickorlando.comSpace Perspective's Spaceship Neptune capsule lifts off from ship on test flightSeptember 16, 2024 | floridatoday.comNeptune Beach, FL Weather ConditionsAugust 30, 2024 | wunderground.comHigh-tech wizardry and old-fashioned care will grow pot indoors at Neptune's GardenAugust 30, 2024 | app.comYour Daily Horoscope: Sunday, August 25, 2024August 25, 2024 | msn.comExploring Alternative Wellness Options for Stress Management & RelaxationAugust 25, 2024 | spacecoastdaily.comSunrise Total Mind Wellness closing its doors in New BraunfelsAugust 18, 2024 | herald-zeitung.comNeptune Medical raises $97M for surgical robotics, spins out Jupiter EndovascularAugust 16, 2024 | therobotreport.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNBY, ACST, NEPT, and ASND Company DescriptionsAcasti Pharma NASDAQ:ACSTAcasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.Ascendis Pharma A/S NASDAQ:ASND$157.27 -4.73 (-2.92%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$157.29 +0.02 (+0.01%) As of 05/27/2025 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.NovaBay Pharmaceuticals NYSE:NBY$0.57 0.00 (-0.68%) As of 05/27/2025 03:59 PM EasternNovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.Neptune Wellness Solutions NASDAQ:NEPTNeptune Wellness Solutions Inc., a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils. Its custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Wellness Solutions Inc. was founded in 1998 and is headquartered in Laval, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Apple Sinks After New 25% Tariff Announcement—What's The Bottom? MarketBeat Week in Review – 05/19 - 05/23 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
